A novel defined risk signature based on pyroptosis-related genes can predict the prognosis of prostate cancer

Abstract

Background Pyroptosis can not only inhibit the occurrence and development of tumors but also develop a microenvironment conducive to cancer growth. However, pyroptosis research in prostate cancer (PCa) has rarely been reported. Methods The expression profile and corresponding clinical data were obtained from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Patients were divided into different clusters using consensus clustering analysis, and differential genes were obtained. We developed and validated a prognostic biomarker for biochemical recurrence (BCR) of PCa using univariate Cox analysis, Lasso-Cox analysis, Kaplan–Meier (K–M) survival analysis, and time-dependent receiver operating characteristics (ROC) curves. Results The expression levels of most pyroptosis-related genes (PRGs) are different not only between normal and tumor tissues but also between different clusters. Cluster 2 patients have a better prognosis than cluster 1 patients, and there are significant differences in immune cell content and biological pathway between them. Based on the classification of different clusters, we constructed an eight genes signature that can independently predict the progression-free survival (PFS) rate of a patient, and this signature was validated using a GEO data set (GSE70769). Finally, we established a nomogram model with good accuracy. Conclusions In this study, PRGs were used as the starting point and based on the expression profile and clinical data, a prognostic signature with a high predictive value for biochemical recurrence (BCR) following radical prostatectomy (RP) was finally constructed, and the relationship between pyroptosis, immune microenvironment, and PCa was explored, providing important clues for future research on pyroptosis and immunity.

A comprehensive analysis of ncRNA-mediated interactions reveals potential prognostic biomarkers in prostate adenocarcinoma

“…2 F), which further validated the effectiveness and high accuracy of the prognosis model. Compared with other relevant reported risk models [19] , [20] , [21] , our risk score model had better effect and was robust ( Figure S2 B-S2D). Simultaneously, to avoid the potential influence of down-regulated gene (FAM107A), we also analyzed another 7 up-regulated genes, and similar results could be found ( Figure S2 E-S2F).…”

Identification of pyroptosis-related lncRNA signature and AC005253.1 as a pyroptosis-related oncogene in prostate cancer

“…In addition, the 1-, 3-, and 5-year AUC values in the test set also had desirable results. Our risk model had excellent predictive power compared to other published pyroptosis-based prognostic models in PCa ( 45 , 46 ). Different from the direct use of Lasso to build a prognostic model of eight pyroptosis-related genes in the study of Wang et al.…”

A newly identified pyroptosis-related gene signature for predicting prognosis of patients with hepatocellular cancer

“…Pyroptosis, a novel kind of programmed cell death, has emerged as an innovative target of investigation in cancer. Numerous research reports have illustrated a strong correlation between pyroptosis and the onset and progression of many malignancies ( 14 - 16 ). Nonetheless, the extent to which pyroptosis-related genes are associated with patient survival and their involvement in HCC has not been elucidated.…”